Ifosfamide chemotherapy for pancreatic carcinoma

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

From April 1982 through February 1984, 29 patients with pancreatic cancer were treated with ifosfamide (1.25-1.5 g/m2 on days 1-5) +N-acetylcysteine (NAC) 2 g p.o. every 6 h on days 1-7 every 3 weeks. In responding patients without serious toxicity, subsequent courses of ifosfamide were escalated every 3 weeks by 0.25 g/m2 per day to a maximum of 2 g/m2 per day, with escalation of NAC to 12 g/day. Patients with KPS<50, serum creatinine or bilirubin>2 mg/d l, or obstructive uropathy were ineligible. The median age was 54 (range 36-78), median KPS 70, and median pretreatment weight loss 9 kg. Toxicity included nausea, vomiting, moderate myelosuppression, and occasional mental confusion. Hematuria (>11 RBC/HPF) developed in only 1/29 courses (17 patients) of ifosfamide at ≥1.75 g/m2 per day, and in 7/52 courses (27 patients) overall (13%). Of 27 evaluable patients 6 responded (22%), including 1 with complete response. The median survival was 6 months. Based upon these results, we are currently evaluating ifosfamide + 5-fluorouracil in pancreatic cancer.

Original languageEnglish
JournalCancer Chemotherapy and Pharmacology
Volume18
Issue number2 Supplement
DOIs
StatePublished - Jan 1986

Fingerprint

Ifosfamide
Chemotherapy
Drug Therapy
Acetylcysteine
Toxicity
Pancreatic Neoplasms
Fluorouracil
Hematuria
Nausea
Vomiting
Pancreatic Carcinoma
Weight Loss
Survival

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Ifosfamide chemotherapy for pancreatic carcinoma. / Einhorn, Lawrence; Loehrer, Patrick.

In: Cancer Chemotherapy and Pharmacology, Vol. 18, No. 2 Supplement, 01.1986.

Research output: Contribution to journalArticle

@article{48ccb5b30e614493aadbc52395642273,
title = "Ifosfamide chemotherapy for pancreatic carcinoma",
abstract = "From April 1982 through February 1984, 29 patients with pancreatic cancer were treated with ifosfamide (1.25-1.5 g/m2 on days 1-5) +N-acetylcysteine (NAC) 2 g p.o. every 6 h on days 1-7 every 3 weeks. In responding patients without serious toxicity, subsequent courses of ifosfamide were escalated every 3 weeks by 0.25 g/m2 per day to a maximum of 2 g/m2 per day, with escalation of NAC to 12 g/day. Patients with KPS<50, serum creatinine or bilirubin>2 mg/d l, or obstructive uropathy were ineligible. The median age was 54 (range 36-78), median KPS 70, and median pretreatment weight loss 9 kg. Toxicity included nausea, vomiting, moderate myelosuppression, and occasional mental confusion. Hematuria (>11 RBC/HPF) developed in only 1/29 courses (17 patients) of ifosfamide at ≥1.75 g/m2 per day, and in 7/52 courses (27 patients) overall (13{\%}). Of 27 evaluable patients 6 responded (22{\%}), including 1 with complete response. The median survival was 6 months. Based upon these results, we are currently evaluating ifosfamide + 5-fluorouracil in pancreatic cancer.",
author = "Lawrence Einhorn and Patrick Loehrer",
year = "1986",
month = "1",
doi = "10.1007/BF00647452",
language = "English",
volume = "18",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2 Supplement",

}

TY - JOUR

T1 - Ifosfamide chemotherapy for pancreatic carcinoma

AU - Einhorn, Lawrence

AU - Loehrer, Patrick

PY - 1986/1

Y1 - 1986/1

N2 - From April 1982 through February 1984, 29 patients with pancreatic cancer were treated with ifosfamide (1.25-1.5 g/m2 on days 1-5) +N-acetylcysteine (NAC) 2 g p.o. every 6 h on days 1-7 every 3 weeks. In responding patients without serious toxicity, subsequent courses of ifosfamide were escalated every 3 weeks by 0.25 g/m2 per day to a maximum of 2 g/m2 per day, with escalation of NAC to 12 g/day. Patients with KPS<50, serum creatinine or bilirubin>2 mg/d l, or obstructive uropathy were ineligible. The median age was 54 (range 36-78), median KPS 70, and median pretreatment weight loss 9 kg. Toxicity included nausea, vomiting, moderate myelosuppression, and occasional mental confusion. Hematuria (>11 RBC/HPF) developed in only 1/29 courses (17 patients) of ifosfamide at ≥1.75 g/m2 per day, and in 7/52 courses (27 patients) overall (13%). Of 27 evaluable patients 6 responded (22%), including 1 with complete response. The median survival was 6 months. Based upon these results, we are currently evaluating ifosfamide + 5-fluorouracil in pancreatic cancer.

AB - From April 1982 through February 1984, 29 patients with pancreatic cancer were treated with ifosfamide (1.25-1.5 g/m2 on days 1-5) +N-acetylcysteine (NAC) 2 g p.o. every 6 h on days 1-7 every 3 weeks. In responding patients without serious toxicity, subsequent courses of ifosfamide were escalated every 3 weeks by 0.25 g/m2 per day to a maximum of 2 g/m2 per day, with escalation of NAC to 12 g/day. Patients with KPS<50, serum creatinine or bilirubin>2 mg/d l, or obstructive uropathy were ineligible. The median age was 54 (range 36-78), median KPS 70, and median pretreatment weight loss 9 kg. Toxicity included nausea, vomiting, moderate myelosuppression, and occasional mental confusion. Hematuria (>11 RBC/HPF) developed in only 1/29 courses (17 patients) of ifosfamide at ≥1.75 g/m2 per day, and in 7/52 courses (27 patients) overall (13%). Of 27 evaluable patients 6 responded (22%), including 1 with complete response. The median survival was 6 months. Based upon these results, we are currently evaluating ifosfamide + 5-fluorouracil in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0022895120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022895120&partnerID=8YFLogxK

U2 - 10.1007/BF00647452

DO - 10.1007/BF00647452

M3 - Article

C2 - 3815719

AN - SCOPUS:0022895120

VL - 18

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2 Supplement

ER -